Stock Research: OKYO Pharma

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

OKYO Pharma

NAQ:OKYO GG00BMFG5F62
62
  • Value
    84
  • Growth
    65
  • Safety
    Safety
    18
  • Combined
    56
  • Sentiment
    52
  • 360° View
    360° View
    62
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 62 (better than 62% compared with alternatives), overall professional sentiment and financial characteristics for the stock OKYO Pharma are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for OKYO Pharma. The consolidated Value Rank has an attractive rank of 84, which means that the share price of OKYO Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 84% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 65, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 52. But the company’s financing is risky with a Safety rank of 18. This means 82% of comparable companies have a safer financing structure than OKYO Pharma. ...read more

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 n/a n/a n/a
Growth
65 n/a n/a n/a
Safety
Safety
18 n/a n/a n/a
Sentiment
52 n/a n/a n/a
360° View
360° View
62 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
63 n/a n/a n/a
Opinions Change
95 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
32 n/a n/a n/a
Sentiment
52 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
84 n/a n/a n/a
Growth
65 n/a n/a n/a
Safety Safety
18 n/a n/a n/a
Combined
56 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
n/a n/a n/a n/a
Price vs. Earnings (P/E)
95 n/a n/a n/a
Price vs. Book (P/B)
95 n/a n/a n/a
Dividend Yield
1 n/a n/a n/a
Value
84 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
n/a n/a n/a n/a
Profit Growth
29 n/a n/a n/a
Capital Growth
75 n/a n/a n/a
Stock Returns
53 n/a n/a n/a
Growth
65 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
58 n/a n/a n/a
Refinancing
12 n/a n/a n/a
Liquidity
21 n/a n/a n/a
Safety Safety
18 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to OKYO Pharma and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Metlen Energy & Metals

LSE:MTLN
Country: United Kingdom
Industry: Industrial Conglomerates
Size: Large
Full Stock Analysis

ZIGUP

LSE:ZIG
Country: United Kingdom
Industry: Specialized Consumer Services
Size: Medium
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: